Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMID™), in the treatment of patients with metastatic malignant melanoma and other advanced cancers. A total of 20 heavily pretreated patients received a dose-escalating regimen of oral CC-5013. Maximal tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, J B, Michael, A, Clarke, I A, Dredge, K, Nicholson, S, Kristeleit, H, Polychronis, A, Pandha, H, Muller, G W, Stirling, D I, Zeldis, J, Dalgleish, A G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410215/
https://www.ncbi.nlm.nih.gov/pubmed/14997189
http://dx.doi.org/10.1038/sj.bjc.6601579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410215/
https://www.ncbi.nlm.nih.gov/pubmed/14997189
http://dx.doi.org/10.1038/sj.bjc.6601579

Ejemplares similares